thought test rais po
host virtual roadshow management
host virtual investor meet dgx ceo steve rusckowski evp
gener diagnost jim davi ir shawn bevec main focu dgx covid-
test test capac revenu opportun provid takeaway
meet test scenario analysi exhibit
test big opportun mani variabl
call note volum declin inclus
test point expans molecular mdx serolog test capac
addit favor reimburs could help off-set headwind
also drive signific upsid thu far us mdx test
mainli util hospit patient underli condit
symptomat frontlin worker howev capac come line
popul elig mdx test grow see strong demand continu
await progress vaccin serolog demand harder assess given
question test perform util capacity/competit
rais est po still much learn
overal posit dgx test opportun rais est
po howev given recent stock price action feel signific test
tailwind alreadi price share reiter neutral rate
pend clariti preval immunolog serolog
attempt reopen part us without adequ test fare overal us
test roadmap rais sale ep est
test tailwind upsid potenti test util
durat greater expect long-term effort develop altern
faster cheaper and/or poc test option deliv central lab may
well-posit still much learn higher est
rais po still base ev/ebitda multipl estimate
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
poc point care
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
largest provid clinic diagnost
test relat servic deliv
nation network full-servic clinic
laboratori patient servic center
clinic lab oper highli competit
price-deflationari environ despit
signific market headwind last year
manag deliv better expect
result due improv execut although
long-term see upsid potenti elev
lab consolid catalyz medicar
opportun monet lab data near-
term visibl still somewhat limit keep us
sidelin
base case test demand base white hous test blue print releas
earlier week test popul monthli assum mdx
serolog test use assum test sustain
test guidelin expand await news vaccin dgx test
capac later quarter cap current goal june detail
view done excel job keep analyst investor well
inform complex situat current ramp
capac mdx serolog test compani current mdx capac
run tests/day dgx capac includ ldt laboratori develop test run
tmo pcr machin run roch coba run panther
fusion compani plan add anoth tests/day june primarili
holx new test panther platform link reimburs mdx test
higher throughput platform increas compani
discuss commerci payer rate mdx model assum asp
upsid potenti commerci payer come rate
compani disclos rel profit test date
run mdx test us
serolog test note ramp capac tests/month use
combin pki euroimmun diasorin ortho clinic diagnost
immunoassay platform hope reimburs line
averag revenu per requisit low model purpos
refer reimburs zika test given addit cost
associ covid assay ppe increment report requir
believ lab may abl get zika rate variabl consid
includ serolog test use employ demand
gener public clariti test guidelin govern agenc reimburs
test perform competit increment inform human immun
respons infect
total us covid test volum mn
us popul mn
covid serolog test revenu mn
covid mdx test revenu mn
key point management meet
secur suppli chain capac continu ramp
key bottleneck test earli outbreak shortag reagent
note experienc reagent shortag mdx tests/day capac
expect experi bottleneck continu ramp add
anoth tests/day addit management note work close key
vendor roch secur suppli chain reagent
well product necessari self-collect tradit physician kit includ
swab serolog test management note feel confid get
serolog test per day without buy new platform current
monitor reagent avail note run serolog test
igg antibodi seen high specif
routin test volum return
key focu routin test volum begin
bounc back highli depend feder state guidanc regard
durat lockdown management note current volum variabl test
categori cancer test volum well test
volum averag physician offic
hospit reopen routin visit elect procedur ob/gyn management predict
gener health well like begin ramp slowli patholog test
biopsi bounc back quickli
at-hom test kit could key broader test
begin offer at-hom test kit allow individu collect
sampl home mail test lab receiv result electron
test number benefit includ allevi ppe healthcar
provid shortag concern test becom widespread addit
test could take advantag abil order via telehealth network dgx
on-line order platform state current requir physician prescript
order test well quest app receiv result keep patient
away alreadi overburden healthcar system especi crucial
employ consid larg scale test workforc attempt return
price object base ev/ebitda multipl est
in-lin compani histor median year forward multipl view
multipl appropri given play key role fight
upsid risk stronger expect demand longer durat
test faster expect materi hospit lab consolid trend margin
expans due higher specialti test mix faster volum growth consum
downsid risk greater expect price headwind lower expect test
volum growth challeng tie outbreak competit execut risk
integr risk data privaci risk regulatori risk
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
